Hemophilia A

CHOP researchers developed a factor VIII variant that led to safe and long-lasting therapeutic results in preclinical models.

CHOP's NoT Bleeding Program will conduct clinical trials to develop the next generation of therapeutics for hemophilia A, B, and other bleeding disorders.

Dr. Lindsey George and colleagues report safe and sustained expression following hemophilia A gene therapy.

Two exciting lines of research build on what we know about hemophilia to improve existing treatments.

New FVIII Center has four projects under way from diverse perspectives to find novel approaches for therapeutic intervention in hemophilia A.

For children with hemophilia, every new research advance is a step toward a life filled with more activity, freedom, and adventure. The genetic condition, which affects roughly one in 5,000 births, causes children to bleed and bruise more easily than others – meaning that a simple cut, scrape, or small surgery can result in uncontrollable and excessive bleeding. While hemophilia